Stamford, CT -- (SBWIRE) -- 01/03/2014 -- Jet Life Penny Stocks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Commercial International Bk (Eypt) (ADR) (OTCMKTS:CIBEY), Cellceutix Corp (OTCMKTS:CTIX), Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY), Gazprom OAO (ADR) (OTCMKTS:OGZPY)
Commercial International Bk (Eypt) (ADR) (OTCMKTS:CIBEY) opened the session at $4.31, trading in a range of $4.20 - $04.49. The stock showed a negative performance of -4.44% in the last trading session from its previous close of $4.50 and closed at $4.30. The stock traded on a volume of 39,058 shares and the average volume of the stock remained 23,729 shares. Commercial International Bank (Egypt) S.A.E. provides various banking services in Egypt. It operates through four segments: Corporate Banking, Investment Banking, Retail Banking, and Others. The company offers deposit products, such as current and savings accounts, and time deposits; certificates of deposit; and minor, youth, senior citizen, and care accounts. It provides loans comprising auto loans and personal loans; residential property finance; CIB wealth; phone banking, electronic settlement services.
Has CIBEY Found The Bottom and Ready To Move Up? Find Out Here
Cellceutix Corp (OTCMKTS:CTIX) traded 351,305 shares in the last business day while the average volume of the stock remained 212,463 shares. The stock showed a negative movement of -4.40% to end at $2.00. The 52 week range of the stock remained $1.40 - $2.42. Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease. Its product candidates include Kevetrin, which is in Phase 1 trial for various solid tumor cancer types in patients with advanced-stage cancers; and various preclinical stage products comprising KM-133 for the treatment of psoriasis; KM 391 for the treatment of autism; KM 277 for the treatment of arthritis; and KM 278 for the treatment of asthma and osteoarthritis.
Has CTIX Found The Bottom And Ready To Gain Momentum? Find Out Here
Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY) reported 491,063 shares were exchanged during the last trade, while the average volume is about 420,761 shares. The stock dropped -4.29% and finished the day at $16.52. The beta of the stock is recorded at 0.88. Deutsche Telekom AG operates as an integrated telecommunication company. The company offers fixed-network services, such as voice and data communication services based on fixed-network and broadband technology; and sells terminal equipment and other hardware, as well as services to resellers.
Why Should Investors Buy DTEGY After the Recent Fall? Just Go Here and Find Out
Gazprom OAO (ADR) (OTCMKTS:OGZPY) shares dropped -4.16 percent from its previous close of $8.65 to close at $8.29. Traded with volume of 368,497 shares in the prior session and the average volume of the stock remained 685,201 shares. OAO Gazprom, together with its subsidiaries, engages in the exploration and production of oil and gas. It produces crude oil and gas condensate. The company also engages in the storage, transportation, and sale of gas; and processing of oil, gas condensate, and other hydrocarbons, as well as sale of refined products. In addition, it is involved in the generation and sale of electric and heat energy.
Will OGZPY Get Buyers Even After The Recent Rally? Find Out Here
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Our Penny Stock Newsletter also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Read full disclaimer at: http://www.jetlifepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)